Browsing by Author Salles, Gilles

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2018Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyTrotman, Judith; Balasubramanian, Sriram; Caballero, Dolores; Cheson, Bruce D; Damle, Rajendra; Deshpande, Sanjay; Fowler, Nathan; Gartenberg, Gary; Gopal, Ajay; Hess, Georg; Hou, Jing-Zhou; Jurczak, Wojciech; Lill, Michael; Martin, Peter; Morton, James; Radford, John; Salles, Gilles; Schaffer, Michael; Schuster, Stephen; Spencer, Andrew; Vermeulen, Jessica; Vitolo, Umberto; Wang, Shean-Sheng; Yacoub, Abdulraheem; Concord Clinical School: MedicineIbrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study, Journal of Clinical Oncology, vol.36, 23, 2018,pp 2405-2412
2014PET/CT assessment in follicular lymphoma using standardized criteria: Central review in the PRIMA studyFulham, Michael; Trotman, Judith; Fournier, Marion; Lamy, Thierry; Meignan, Michel; Ricard, Fabien; Salles, Gilles; Tychyj-Pinel, Christelle; Vera, Pierre; Central Clinical School: Medicine; Concord Clinical School: MedicinePET/CT assessment in follicular lymphoma using standardized criteria: Central review in the PRIMA study, European Journal of Nuclear Medicine and Molecular Imaging, vol.41, 3, 2014,pp 408-415
2011Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trialEstell, Jane; Belada, David; Bouabdallah, Réda; Brice, Pauline; Catalano, John Vincent; et al, various; Feugier, Pierre; López-Guillermo, Armando; Offner, Fritz; Salles, Gilles; Seymour, John F.; Xerri, Luc; Concord Clinical School: MedicineRituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, The Lancet, vol.377, 9759, 2011,pp 42-51